Top 10 Companies in the United States Antiserum Market (2026): Market Leaders Driving Innovation

MARKET INSIGHTS

The United States Antiserum market size was valued at USD 345.6 million in 2024. The market is projected to grow from USD 366.2 million in 2025 to USD 546.3 million by 2034, exhibiting a CAGR of 5.9% during the forecast period.

Antiserum represents a biological product containing antibodies, primarily utilized in medical treatments and research applications. These preparations play a vital role in providing passive immunity against specific pathogens or toxins, aiding in diagnostics, therapy for infectious diseases, and immunological studies. Common types encompass antitoxin serums for neutralizing toxins, antibacterial and antiviral serums for combating bacterial and viral infections, as well as anti‑Rh serums for blood typing and hemolytic disease prevention.

The market is showing robust expansion, fueled by heightened biomedical research and the rising need for therapeutic interventions in immunology and infectious diseases. Furthermore, technological advancements in production techniques have enhanced product specificity and quality, while stricter quality control standards ensure reliability. The growing popularity of customized antiserum solutions in laboratory and clinical settings continues to drive demand. Key players such as Pfizer Inc., Merck & Co., Inc., and CSL Behring dominate the landscape, offering diverse portfolios that support ongoing innovations and market growth.

United States Antiserum Market – View in Detailed Research Report

Top 10 Companies in the United States Antiserum Market (2026)

10️⃣ 1. Pfizer Inc.

Headquarters: New York, NY, USA
Key Offering: Antitoxin and Antiviral Serums, Immunoglobulin Products

Pfizer has a long history of developing plasma‑derived therapies and has expanded its antiserum portfolio to include next‑generation antiviral serums for emerging viral threats. The company’s focus on scalable bioprocessing and global supply chains positions it as a leader in meeting the rising demand for high‑purity antiserum.

Sustainability & Growth Initiatives:

• Investment in recombinant antibody platforms to reduce animal sourcing.
• Partnerships with academic institutions for rare disease antiserum research.
• Commitment to carbon‑neutral manufacturing by 2030.

9️⃣ 2. Merck & Co., Inc.

Headquarters: Kenilworth, NJ, USA
Key Offering: Antitoxin Serums, Anti‑Rh, and Biologic Immunoglobulins

Merck’s robust R&D pipeline includes advanced antiserum formulations for both therapeutic and diagnostic applications. The company’s focus on precision medicine and global distribution networks ensures rapid deployment across diverse markets.

Sustainability & Growth Initiatives:

• Expansion of plasma fractionation facilities with lower environmental impact.
• Collaboration with biotech startups for hyper‑immune globulin development.
• Targeted reduction of waste streams in antibody production.

8️⃣ 3. CSL Behring

Headquarters: King City, CA, USA (global headquarters in Australia)
Key Offering: Antitoxin Serums, Antibacterial, and Antiviral Serums

CSL Behring’s expertise in plasma‑derived products and advanced purification technologies drives its leadership in antiserum quality and consistency. The company’s global supply chain supports rapid response to emerging infectious disease outbreaks.

Sustainability & Growth Initiatives:

• Investment in renewable energy for manufacturing sites.
• Development of recombinant antiserum platforms to reduce animal use.
• Commitment to 100% recyclable packaging by 2035.

7️⃣ 4. Grifols S.A.

Headquarters: Barcelona, Spain
Key Offering: Antitoxin and Antiviral Serums, Plasma‑Derived Products

Grifols combines its extensive plasma fractionation capabilities with advanced antibody purification to deliver high‑quality antiserum solutions for both therapeutic and research markets.

Sustainability & Growth Initiatives:

• Implementation of water‑saving technologies in plasma processing.
• Partnerships with EU research institutes for rare disease antiserum.
• Investment in circular economy practices for bioproducts.

6️⃣ 5. Sanofi S.A.

Headquarters: Paris, France
Key Offering: Antitoxin Serums, Immunoglobulin Products

Sanofi’s focus on vaccine‑derived antiserum and collaboration with global health agencies positions it as a key player in combating infectious diseases worldwide.

Sustainability & Growth Initiatives:

• Reduction of carbon footprint across manufacturing sites.
• Development of plant‑based antibody production.
• Strategic alliances for global access to antiserum.

5️⃣ 6. Takeda Pharmaceutical Company

Headquarters: Tokyo, Japan
Key Offering: Antiviral Serums, Antitoxin Products

Takeda’s investment in precision medicine and advanced antibody engineering enhances its antiserum portfolio, particularly for rare viral diseases.

Sustainability & Growth Initiatives:

• Commitment to zero waste in production by 2030.
• Collaboration with global research networks for rare disease antiserum.
• Investment in renewable energy for manufacturing.

4️⃣ 7. Emergent BioSolutions

Headquarters: Germantown, MD, USA
Key Offering: Hyper‑immune Globulin, Antitoxin Serums for Biodefense

Emergent BioSolutions specializes in high‑potency antiserum for biodefense and emerging pathogens, leveraging rapid development pipelines and advanced purification methods.

Sustainability & Growth Initiatives:

• Adoption of closed‑loop bioreactor systems.
• Partnerships with defense research agencies.
• Focus on scalable production for emergency response.

3️⃣ 8. ADMA Biologics, Inc.

Headquarters: San Diego, CA, USA
Key Offering: Custom Antiserum Solutions, Recombinant Antibodies

ADMA Biologics provides tailored antiserum solutions for research and clinical applications, utilizing advanced recombinant technologies to meet specific client needs.

Sustainability & Growth Initiatives:

• Implementation of green chemistry in antibody production.
• Collaboration with academic labs for precision immunology.
• Commitment to sustainable sourcing of raw materials.

2️⃣ 9. Bayer AG

Headquarters: Leverkusen, Germany
Key Offering: Antitoxin Serums, Immunoglobulin Products

Bayer’s integrated biopharma platform supports high‑quality antiserum manufacturing, with a focus on regulatory compliance and product safety.

Sustainability & Growth Initiatives:

• Reduction of greenhouse gas emissions across facilities.
• Investment in renewable energy for production.
• Partnerships for sustainable supply chain management.

1️⃣ 10. Bristol Myers Squibb Co.

Headquarters: New York, NY, USA
Key Offering: Antiviral Serums, Antitoxin Products

Bristol Myers Squibb’s focus on oncology and immunology translates into a robust antiserum portfolio for both therapeutic and diagnostic use.

Sustainability & Growth Initiatives:

• Implementation of circular economy practices.
• Collaboration with global health initiatives.
• Investment in next‑generation antibody technologies.

Download FREE Sample Report: United States Antiserum Market – View in Detailed Research Report

Get Full Report Here: United States Antiserum Market – View in Detailed Research Report

Outlook

The United States Antiserum market is projected to grow from USD 366.2 million in 2025 to USD 546.3 million by 2034, reflecting a steady CAGR of 5.9% over the forecast period. This growth is driven by sustained investments in biomedical research, expanding therapeutic applications, and continuous innovation in production technologies that enhance product quality and specificity.

Future Trends

Key future trends include the rapid adoption of recombinant antibody platforms, increased focus on precision medicine and personalized antiserum therapies, and a shift toward sustainable manufacturing practices. Emerging applications in oncology, autoimmunity, and telemedicine integration are expected to broaden the market scope, while regulatory advancements and global collaborations will further accelerate growth.